Crop Mycosis (Thrush, Candidiasis)

CROP MYCOSIS (THRUSH, CANDIDIASIS) • Most common mycotic diseases of poultry • Most important in young poults and occasionally cage layers ETIOLOGY Candida albicans • Very ubiquitous in normal flora • Follows debilitating condition • Broad spectrum antibiotics favor development by disruption of normal flora balance. • Seen in “spiking mortality” poults due to antibiotic use. INCUBATION PERIOD • Experimentally about 30 days, but has been found in 7-14 day old poults • Induced by giving sugar water to poults. COURSE OF DISEASE • 3 to 4 weeks • May become chronic, then several weeks MORTALITY • Poults and chicks - up to 20 to 30% • Older birds - after 4 weeks usually low METHOD OF SPREAD 1. Drinking water a) associated with unsanitary, over-crowded condition b) slimy water founts, wet litter 2. Infected birds source of contamination 3. Cages due to decreased bacterial competition No contact with feces. SYMPTOMS • Poor growth • "Sick chick attitude" • In layers - decrease egg production 15 to 20% • Birds vomit in feed trough POSTMORTEM LESIONS • Non-inflammatory - thickened crop and/or mouth • White, circular, raised ulcer-like formation • Pseudomembrane • Proventriculitis Gizzard erosion • Can occasionally be cultured from the liver. • May cause splotchy hemorrhages in the digestive tract. Crop mycosis Crop mycosis Crop mycosis Crop mycosis Esophageal lesion Gizzard erosion Enteritis DIAGNOSIS • Suggestive - typical lesions, non-inflammatory • Positive - isolation and identification – Special medias used: • Corn meal agar • Biggy agar - brown colony with white halo Biggy agar Wet mount TREATMENT Mycostatin (nystatin) 100 gm/ton 7-10 days CuSO4 1:2000 in water, 1-3 #/ton Chlorine in the drinking water at 5 ppm. Clean up PREVENTION • Maintain sanitation • Avoid prolonged use of broad spectrum antibiotics • Mycostatin (nystatin) in feed 50 gm/ton • Ca++ or Na+ propionate in feed 3-5 #/ton • Propionic acid antifungals in feed 1-4 #/ton. (Depends on concentration of active ingredient). .

Copy Link

Recommended publications

Prostatic Cryptococcosis - a Case Report
Received: November 8, 2007 J. Venom. Anim. Toxins incl. Trop. Dis. Accepted: April 1, 2008 V.14, n.2, p.378-385, 2008. Abstract published online: April 2, 2008 Case report. Full paper published online: May 31, 2008 ISSN 1678-9199. PROSTATIC CRYPTOCOCCOSIS - A CASE REPORT CHANG M. R. (1), PANIAGO A. M. M. (2), SILVA M. M. (3), LAZÉRA M. S. (4), WANKE B. (4) (1) Department of Pharmacy-Biochemistry, Federal University of Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul State, Brazil; (2) Department of Internal Medicine, UFMS, Campo Grande, Mato Grosso do Sul State, Brazil; (3) Medicine Program, University for Development of the State and the Pantanal Region (UNIDERP), Campo Grande, Mato Grosso do Sul State, Brazil; (4) Mycology Service Evandro Chagas Institute of Clinical Research (IPEC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Rio de Janeiro State, Brazil. ABSTRACT: Cryptococcosis is a systemic mycosis usually affecting immunodeficient individuals. In contrast, immunologically competent patients are rarely affected. Dissemination of cryptococcosis usually involves the central nervous system, manifesting as meningitis or meningoencephalitis. Prostatic lesions are not commonly found. A case of prostate cryptococcal infection is presented and cases of prostatic cryptococcosis in normal and immunocompromised hosts are reviewed. A fifty-year-old HIV-negative man with urinary retention and renal insufficiency underwent prostatectomy due to massive enlargement of the organ. Prostate histopathologic examination revealed encapsulated yeast-like structures. After 30 days, the patient’s clinical manifestations worsened, with headache, neck stiffness, bradypsychia, vomiting and fever. Direct microscopy of the patient’s urine with China ink preparations showed capsulated yeasts, and positive culture yielded Cryptococcus neoformans.
[Show full text]
Fungal Foot Infection: the Hidden Enemy?
Clinical REVIEW Fungal foot infection: the hidden enemy? When discussing tissue viability in the lower limb, much attention is focused on the role of bacterial infection. However, fungal skin infection is a more frequent and more recurrent pathogen which often goes undetected by the practitioner and patient alike. Potentially, untreated fungal foot infection can facilitate secondary problems such as superficial bacterial infections, or, more seriously, lower limb cellulitis. Often simple measures can prevent fungal foot infection and therefore reduce the possibility of complications. This article will review the presentation of tinea pedis and onychomycosis, their effects and management. Ivan Bristow, Manfred Mak Under occlusive and humid conditions increased risk of acquiring the infection. KEY WORDS the fungal hyphae then develop and Patients with diabetes show an increased invade the deeper stratum corneum. susceptibility (Yosipovitch et al, 1998). Fungal Nutrition is afforded by the extra-cellular Boyko et al (2006) have identified the Tinea pedis secretion of proteolytic and keratolytic presence of tinea to be a predictor of Onchomycosis enzymes breaking down the complex foot ulceration in a diabetic population. Cellulitis keratin into simple molecules which can The reason for an increased prevalence be absorbed by the organism (Kaufman in patients with diabetes remains under- et al, 2007). researched. It has been proposed that peripheral neuropathy renders the foot Epidemiology of fungal foot infection insensate reducing individual awareness inea pedis (athlete’s foot) is an Fungal foot infection (FFI) is the most to the presence of infection. Eckhard et inflammatory condition and common infection found on the foot. al (2007) discovered a high prevalence Trepresents the most common of Seldom seen before puberty, the in patients with type 2 diabetes who all the superficial fungal skin infections prevalence rises with age, peaking in the exhibited a lack of sweating when tested (Hay, 1993).
[Show full text]
Allergic Bronchopulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis Karen Patterson1 and Mary E. Strek1 1Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois Allergic bronchopulmonary aspergillosis (ABPA) is a complex clinical type of pulmonary disease that may develop in response to entity that results from an allergic immune response to Aspergillus aspergillus exposure (6) (Table 1). ABPA, one of the many fumigatus, most often occurring in a patient with asthma or cystic forms of aspergillus disease, results from a hyperreactive im- fibrosis. Sensitization to aspergillus in the allergic host leads to mune response to A. fumigatus without tissue invasion. activation of T helper 2 lymphocytes, which play a key role in ABPA occurs almost exclusively in patients with asthma or recruiting eosinophils and other inflammatory mediators. ABPA is CF who have concomitant atopy. The precise incidence of defined by a constellation of clinical, laboratory, and radiographic ABPA in patients with asthma and CF is not known but it is criteria that include active asthma, serum eosinophilia, an elevated not high. Approximately 2% of patients with asthma and 1 to total IgE level, fleeting pulmonary parenchymal opacities, bronchi- 15% of patients with CF develop ABPA (2, 4). Although the ectasis, and evidence for sensitization to Aspergillus fumigatus by incidence of ABPA has been shown to increase in some areas of skin testing. Specific diagnostic criteria exist and have evolved over the world during months when total mold counts are high, the past several decades. Staging can be helpful to distinguish active disease from remission or end-stage bronchiectasis with ABPA occurs year round, and the incidence has not been progressive destruction of lung parenchyma and loss of lung definitively shown to correlate with total ambient aspergillus function.
[Show full text]
Mycosis Fungoides and Sézary Syndrome: an Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy
cancers Review Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy Nuria García-Díaz 1 , Miguel Ángel Piris 2,† , Pablo Luis Ortiz-Romero 3,† and José Pedro Vaqué 1,*,† 1 Molecular Biology Department, Universidad de Cantabria—Instituto de Investigación Marqués de Valdecilla, IDIVAL, 39011 Santander, Spain; [email protected] 2 Department of Pathology, Fundación Jiménez Díaz, CIBERONC, 28040 Madrid, Spain; [email protected] 3 Department of Dermatology, Hospital 12 de Octubre, Institute i+12, CIBERONC, Medical School, University Complutense, 28041 Madrid, Spain; [email protected] * Correspondence: [email protected] † Same contribution. Simple Summary: In the last few years, the field of cutaneous T-cell lymphomas has experienced major advances. In the context of an active translational and clinical research field, next-generation sequencing data have boosted our understanding of the main molecular mechanisms that govern the biology of these entities, thus enabling the development of novel tools for diagnosis and specific therapy. Here, we focus on mycosis fungoides and Sézary syndrome; we review essential aspects of their pathophysiology, provide a rational mechanistic interpretation of the genomic data, and discuss the current and upcoming therapies, including the potential crosstalk between genomic alterations Citation: García-Díaz, N.; Piris, M.Á.; and the microenvironment, offering opportunities for targeted therapies. Ortiz-Romero, P.L.; Vaqué, J.P. Mycosis Fungoides and Sézary Abstract: Primary cutaneous T-cell lymphomas (CTCLs) constitute a heterogeneous group of diseases Syndrome: An Integrative Review of that affect the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) account for the majority the Pathophysiology, Molecular of these lesions and have recently been the focus of extensive translational research.
[Show full text]
Immunotherapy in the Prevention and Treatment of Chronic Fungal Infections
A chance for treatment - immunotherapy in the prevention and treatment of chronic fungal infections Frank L. van de Veerdonk Radboud Center for Infectious diseases (RCI) ESCMID eLibrary © by author Candida infections Mucocutaneous infections Invasive candidiasis Th ESCMIDT helper cells eLibraryPhagocytes © by author Chronic Candida infection 30% to 50% of individuals are colonized with Candida at any given moment, but only rarely causing mucosal infections Even more rarely are these infections chronic However, several clinical syndromes have been described with chronic CandidaESCMIDinfections eLibrary © by author Mucosal host defence against Candida ESCMID eLibrary Nature Microbiol. Reviews 2012 © by author Mucosal host defence against Candida ESCMID eLibrary Nature Microbiol. Reviews 2012 © by author Chronic Candida infections Hyper IgE syndrome (HIES) Dectin-1/CARD9 deficiency Chronic mucocutaneous candidiasis (STAT1 GOF, APECED, IL-17F, IL-17R) ESCMID eLibrary © by author Characteristics of Hyper IgE syndrome ESCMID eLibrary © by author Loss of function STAT3 mutation Heterozygous mutation in STAT3 ESCMIDDominant negative eLibrary © by author Cytokine signalling INTERLEUKIN-6/23 IL-6/IL-23 RECEPTOR STAT3 phosphorylation IL-17 ESCMID eLibrary PMN Levy and Loomis et al, NEJM 2007 © by author Th17 deficiency in HIES IL-17 ESCMID eLibrary IFNg van de Veerdonk et al, Clin Exp Immunol© 2010by author Chronic Candida infections Hyper IgE syndrome (HIES) Dectin-1/CARD9 deficiency Chronic mucocutaneous candidiasis ESCMID eLibrary © by author
[Show full text]
Mucormycosis: Botanical Insights Into the Major Causative Agents
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 8 June 2021 doi:10.20944/preprints202106.0218.v1 Mucormycosis: Botanical Insights Into The Major Causative Agents Naser A. Anjum Department of Botany, Aligarh Muslim University, Aligarh-202002 (India). e-mail: [email protected]; [email protected]; [email protected] SCOPUS Author ID: 23097123400 https://www.scopus.com/authid/detail.uri?authorId=23097123400 © 2021 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 8 June 2021 doi:10.20944/preprints202106.0218.v1 Abstract Mucormycosis (previously called zygomycosis or phycomycosis), an aggressive, liFe-threatening infection is further aggravating the human health-impact of the devastating COVID-19 pandemic. Additionally, a great deal of mostly misleading discussion is Focused also on the aggravation of the COVID-19 accrued impacts due to the white and yellow Fungal diseases. In addition to the knowledge of important risk factors, modes of spread, pathogenesis and host deFences, a critical discussion on the botanical insights into the main causative agents of mucormycosis in the current context is very imperative. Given above, in this paper: (i) general background of the mucormycosis and COVID-19 is briefly presented; (ii) overview oF Fungi is presented, the major beneficial and harmFul fungi are highlighted; and also the major ways of Fungal infections such as mycosis, mycotoxicosis, and mycetismus are enlightened; (iii) the major causative agents of mucormycosis
[Show full text]
Eumycetoma Caused by Cladophialophora Bantiana in a Dog J
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2004, p. 4901–4903 Vol. 42, No. 10 0095-1137/04/$08.00ϩ0 DOI: 10.1128/JCM.42.10.4901–4903.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved. Eumycetoma Caused by Cladophialophora bantiana in a Dog J. Guillot,1* D. Garcia-Hermoso,2 F. Degorce,3 M. Deville,1 C. Calvie´,4 G. Dickele´,5 F. Delisle,6 and R. Chermette1 Service de Parasitologie-Mycologie, UMR BIPAR,1 and Centre de Radiothe´rapie et Scanner,6 Ecole Nationale Ve´te´rinaire d’Alfort, Maisons-Alfort, Centre National de Re´fe´rence Mycologie et Antifongiques, Institut Pasteur, Paris,2 Laboratoire d’Anatomie Pathologique Ve´te´rinaire du Sud-Ouest, Toulouse,3 and Clinique Ve´te´rinaire de la Vieille Poste,4 and Clinique Ve´te´rinaire de Celleneuve,5 Montpellier, France Received 19 April 2004/Accepted 29 May 2004 We report a case of eumycetoma due to Cladophialophora bantiana in a 3-year-old male Siberian Husky living in France. The dog presented a tumefaction on the thorax and deformity of the second and third subjacent ribs, which were surgically removed. Macroscopic black granules were visible on the ribs, and direct microscopic Downloaded from examination revealed their fungal origin. Cultures yielded pure colonies of C. bantiana. The identification of the causative agent was confirmed after amplification and sequence analysis of fungal internal transcribed spacers 1 and 2 and 5.8S ribosomal DNA regions. Surgery and antifungal treatment with oral itraconazole associated with flucytosine allowed apparent cure after a 10-month follow-up. Envenomation with pine processionary caterpillars (Thaumetopoea pityocampa) and subsequently intensive corticotherapy were considered as possible predisposing factors.
[Show full text]
A Study of Superficial Mycosis in Tertiary Care Center, PDU Medical College Rajkot Dr
Saudi Journal of Pathology and Microbiology Abbreviated Key Title: Saudi J Pathol Microbiol ISSN 2518-3362 (Print) |ISSN 2518-3370 (Online) Scholars Middle East Publishers, Dubai, United Arab Emirates Journal homepage: http://scholarsmepub.com/sjpm/ Original Research Article A Study of Superficial Mycosis in Tertiary Care Center, PDU Medical College Rajkot Dr. Bhoomi Rathod1, Dr. Madhulika Mistry2, Krupali Gadhavi3, Dr. Y. S. Goswami, Dr. Asha Mandalia3* 1Tutor, PDPU Medical College & Hospital, Rajkot, Gujarat, India 2Associate Professor, PDPU Medical College & Hospital, Rajkot, Gujarat, India 3Associate Professor, Adani Medical College, G.K.General Hospital Campus, Bhuj, Gujarat 370001, India *Corresponding author: Dr. Asha Mandalia | Received: 05.06.2019 | Accepted: 15.06.2019 | Published: 25.06.2019 DOI:10.21276/sjpm.2019.4.6.6 Abstract Aim: To know the seroprevalence of clinical pattern of dermatophytosis (superficial mycosis) with most common fungal pathogen and association with the occupation in P.D.U. Hospital, Rajkot Gujarat region of the India. Methods: A clinical and mycological study of superficial mycosis was conducted on 250 cases (135 male and 115 female). Direct microscopy by KOH mount and culture was undertaken to isolate the fungal pathogen in each case. Results: 225 out of 250 cases (xxx) were positive by direct microscopy in which 130 (xxx) were positive by culture. The commonest age group involved was 21-30 years.Ladourer were affected in115 case out of 250(47.6%) Tinea corporis was the most common clinical presentation and Trichopyton rubrum was the most commonfungal pathogen isolated followed by Trichopyton mentagrophyte. Conclusion: It was concluded that dermatophytes, are the most common fungal causes of superficial mycosis.
[Show full text]
NCCN Guidelines for Patients Mycosis Fungoides/Sézary Syndrome
our Pleaseonline surveycomplete at NCCN.org/patients/survey NCCN GUIDELINES FOR PATIENTS® 2021 Mycosis Fungoides/ Sézary Syndrome Presented with support from: Available online at NCCN.org/patients Ü Mycosis Fungoides/Sézary Syndrome It's easy to get lost in the cancer world Let NCCN Guidelines for Patients® be your guide 9 Step-by-step guides to the cancer care options likely to have the best results 9 Based on treatment guidelines used by health care providers worldwide 9 Designed to help you discuss cancer treatment with your doctors NCCN Guidelines for Patients® Mycosis Fungoides/Sézary Syndrome, 2021 1 About NCCN Guidelines for Patients® are developed by the National Comprehensive Cancer Network® (NCCN®) NCCN Clinical Practice NCCN Guidelines NCCN Guidelines in Oncology for Patients (NCCN Guidelines®) 9 An alliance of leading 9 Developed by doctors from 9 Present information from the cancer centers across the NCCN cancer centers using NCCN Guidelines in an easy- United States devoted to the latest research and years to-learn format patient care, research, and of experience 9 For people with cancer and education 9 For providers of cancer care those who support them all over the world Cancer centers 9 Explain the cancer care that are part of NCCN: 9 Expert recommendations for options likely to have the NCCN.org/cancercenters cancer screening, diagnosis, best results and treatment Free online at Free online at NCCN.org/patientguidelines NCCN.org/guidelines and supported by funding from NCCN Foundation® These NCCN Guidelines for Patients are based on the NCCN Guidelines® for Primary Cutaneous Lymphomas (Version 1.2021, October 12, 2020).
[Show full text]
Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
American Thoracic Society Documents An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients Andrew H. Limper, Kenneth S. Knox, George A. Sarosi, Neil M. Ampel, John E. Bennett, Antonino Catanzaro, Scott F. Davies, William E. Dismukes, Chadi A. Hage, Kieren A. Marr, Christopher H. Mody, John R. Perfect, and David A. Stevens, on behalf of the American Thoracic Society Fungal Working Group THIS OFFICIAL STATEMENT OF THE AMERICAN THORACIC SOCIETY (ATS) WAS APPROVED BY THE ATS BOARD OF DIRECTORS, MAY 2010 CONTENTS immune-compromised and critically ill patients, including crypto- coccosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; Introduction and rare and emerging fungal infections. Methods Antifungal Agents: General Considerations Keywords: fungal pneumonia; amphotericin; triazole antifungal; Polyenes echinocandin Triazoles Echinocandins The incidence, diagnosis, and clinical severity of pulmonary Treatment of Fungal Infections fungal infections have dramatically increased in recent years in Histoplasmosis response to a number of factors. Growing numbers of immune- Sporotrichosis compromised patients with malignancy, hematologic disease, Blastomycosis and HIV, as well as those receiving immunosupressive drug Coccidioidomycosis regimens for the management of organ transplantation or Paracoccidioidomycosis autoimmune inflammatory conditions, have significantly con- Cryptococcosis tributed to an increase in the incidence of these infections. Aspergillosis Definitive
[Show full text]
Beyond Onychomycosis: Other Nail Dystrophies
BEYOND ONYCHOMYCOSIS: OTHER NAIL DYSTROPHIES Tracey C. Vlahovic, DPM FFPM RCPS (Glasg) Clinical Professor, J Stanley and Pearl Landau Faculty Fellow Temple University School of Podiatric Medicine, Phila, PA CONFLICTS OF INTEREST: ORTHO DERM, BAKO EVALUATION AND TREATMENT ALGORITHM OSI severe: orals (multiple courses), with/without OSI adjunctive topical treatment Onychomycosis Comorbid Conditions? OSI moderate: orals and/or topical OSI mild: Abnormal topical monotherapy Nail Not Differential Appropriate Treatment Onychomycosis Diagnosis OSI, onychomycosis severity index. HOW TO COLLECT NAIL SPECIMEN • Dermatophytes in DSO invade the nail bed rather than the nail plate, the specimen MUST BE OBTAINED from the NAIL BED, which is the greatest concentration of viable fungi • First, Wipe the area with an alcohol pad • Second, debride the nail as usual • Third, take specimen from the nail bed as proximally to the cuticle as possible with a small curette or a #15 scalpel • “If debris is insufficient, material should be obtained from the nail bed. Material should also be obtained from the underside of the nail plate, with emphasis placed on sampling from the advancing infected edge most proximal to the cuticle. This is the area most likely to contain viable hyphae and least likely to contain contaminants” Elewski B E. Clinical pearl: diagnosis of onychomycosis. J Am Acad Dermatol. 1995;32:500–501 NAIL DYSTROPHY • Generalized term • Roughness, Beau’s lines, onychorrhexis, ridging • Acrocyanosis • Alopecia areata • Congenital • Lichen planus • Occupational
[Show full text]
Clotrimazole for Vulvovaginal Candidosis: More Than 45 Years of Clinical Experience
pharmaceuticals Review Clotrimazole for Vulvovaginal Candidosis: More Than 45 Years of Clinical Experience Werner Mendling 1, Maged Atef El Shazly 2 and Lei Zhang 2,* 1 German Center for Infections in Obstetrics and Gynaecology, Heusnerstrasse 40, D-42283 Wuppertal, Germany; [email protected] 2 Bayer Consumer Care AG, Peter Merian-Strasse 84, CH-4002 Basel, Switzerland; [email protected] * Correspondence: [email protected]; Tel.: +41-58-272-7497; Fax: +41-58-272-7902 Received: 1 September 2020; Accepted: 23 September 2020; Published: 25 September 2020 Abstract: Vulvovaginal candidosis is a common disease, and various treatment strategies have emerged over the last few decades. Clotrimazole belongs to the drugs of choice for the treatment of vulvovaginal candidosis. Although available for almost 50 years, systematic reviews on the usefulness of topical clotrimazole across disease severity and populations affected are scarce. Thus, we conducted a systematic literature search in the PubMed and Embase databases to summarize the effectiveness and safety of topical clotrimazole in the treatment of uncomplicated (acute) and complicated vulvovaginal candidosis. In total, 37 randomized controlled studies in women suffering from vaginal yeast infections qualified for inclusion in our review. In women with uncomplicated vulvovaginal candidosis, single intravaginal doses of clotrimazole 500 mg vaginal tablets provided high cure rates and were as effective as oral azoles. A single dose of clotrimazole 500 mg was equipotent to multiple doses of lower dose strengths. Prolonged treatment regimens proved to be effective in severe and recurrent cases as well as in symptomatic pregnant women. It is therefore expected that in the general population, clotrimazole will continue to be widely used in the field of vaginal health in the upcoming years; more so as clotrimazole resistance in vaginal candidosis is rare.
[Show full text]